NASDAQ:PRPH - ProPhase Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 235.12 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.46
▲ +0.28 (3.90%)

This chart shows the closing price for PRPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProPhase Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRPH

Analyst Price Target is $25.00
▲ +235.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ProPhase Labs in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 235.12% upside from the last price of $7.46.

This chart shows the closing price for PRPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in ProPhase Labs.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2021Dawson JamesInitiated CoverageBuy$25.00High
(Data available from 7/23/2016 forward)
ProPhase Labs logo
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.
Read More

Today's Range

Now: $7.46
Low: $7.01
High: $7.46

50 Day Range

MA: $5.91
Low: $4.80
High: $7.46

52 Week Range

Now: $7.46
Low: $1.63
High: $16.04

Volume

241,091 shs

Average Volume

334,345 shs

Market Capitalization

$113.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ProPhase Labs?

The following equities research analysts have issued research reports on ProPhase Labs in the last twelve months: Dawson James, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for PRPH.

What is the current price target for ProPhase Labs?

1 Wall Street analysts have set twelve-month price targets for ProPhase Labs in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 235.1%. Dawson James has the highest price target set, predicting PRPH will reach $25.00 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $25.00 for ProPhase Labs in the next year.
View the latest price targets for PRPH.

What is the current consensus analyst rating for ProPhase Labs?

ProPhase Labs currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRPH will outperform the market and that investors should add to their positions of ProPhase Labs.
View the latest ratings for PRPH.

What other companies compete with ProPhase Labs?

How do I contact ProPhase Labs' investor relations team?

ProPhase Labs' physical mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company's listed phone number is 215-345-0919 and its investor relations email address is [email protected] The official website for ProPhase Labs is www.prophaselabs.com.